Lerociclib in HR+/HER2- advanced breast cancer: a clean strategic shutdown in a saturated class

What was tried

NCT05085002 was a Phase 2, open-label, single-arm study of lerociclib (G1T38, ChEMBL3904602), a selective oral CDK4 and CDK6 inhibitor, in combination with letrozole or fulvestrant, in adults with hormone-receptor-positive (HR+) and HER2-negative locally advanced or metastatic breast cancer. The study was sponsored by EQRx and conducted across United States and ex-US sites between December 2021 and November 2023. Enrollment closed at 100 participants (actual). The dose was lerociclib 150 mg orally twice daily, paired with letrozole 2.5 mg daily for first-line patients or fulvestrant 500 mg intramuscular on the labeled schedule for second-line patients. The primary endpoint was incidence of adverse events and serious adverse events, with secondary endpoints capturing progression-free survival, objective response rate, and pharmacokinetics. ClinicalTrials.gov posted the termination on 2026-05-15 with the explicit note that the closure was driven by corporate changes at EQRx and was not related to efficacy or safety findings with lerociclib (NCT05085002, statusModule).

The biological hypothesis

D-type cyclins activate CDK4 and CDK6 to phosphorylate the retinoblastoma protein (RB1) during G1, releasing E2F transcription factors and committing cells to S phase. Estrogen signaling drives cyclin D1 transcription in HR+ breast cancer, so estrogen blockade plus CDK4/6 inhibition is mechanistically additive on the same axis. Three CDK4/6 inhibitors are already approved in HR+/HER2- metastatic breast cancer: palbociclib (Pfizer, 2015), ribociclib (Novartis, 2017), and abemaciclib (Lilly, 2017), each with phase 3 progression-free survival hazard ratios in the 0.50 to 0.58 range against endocrine therapy alone (PALOMA-2, MONALEESA-2, MONARCH-3). Lerociclib was differentiated on tolerability. Preclinical work by Bisi and colleagues showed less sustained CDK6 inhibition in hematopoietic progenitors, predicting lower neutropenia rates (Bisi et al., Oncotarget 2017, see Sources). A Phase 3 study in China (LEONARDA-1) read out positive with median progression-free survival of 11.0 versus 5.6 months for lerociclib plus fulvestrant against placebo plus fulvestrant in second-line HR+ disease (Xu et al., Nat Commun 2025, see Sources), supporting the program's biological premise.

What actually happened

The trial reached planned primary completion on 2023-11-29 with 100 patients on study and an average exposure of 237.4 days per patient. Top-line safety data have not been posted to ClinicalTrials.gov results. The trial was not stopped for futility, did not trip a Data Safety Monitoring Board signal, and did not surface a new toxicity. Instead, EQRx, the sponsor, announced an all-stock merger with Revolution Medicines in August 2023 and discontinued internal development of all assets including lerociclib (EQRx-Revolution Medicines 8-K, 2023-08-01). The US asset was effectively orphaned. The rights to lerociclib in Greater China remained with Genor Biopharma, which secured Chinese NMPA approval in March 2023 based on LEONARDA-1, but ex-China activities lacked a sponsor of record. NCT05085002 sat in administrative limbo until the formal termination posting in May 2026.

Failure mechanism, best guess

This is a clean strategic_reprioritization, not an efficacy_failure or safety_signal. The mechanism is rate-limited at the corporate layer: EQRx was capitalized to compete on price rather than novel mechanism, and the post-IPO biotech downturn of 2022-2023 collapsed that thesis. Lerociclib lost its development sponsor before the late-stage Western dataset could mature. The competitive context made re-sponsoring uneconomical. Palbociclib, ribociclib, and abemaciclib accounted for 3.4 billion USD, 2.3 billion USD, and 4.6 billion USD respectively in worldwide 2023 sales, and ribociclib has now demonstrated overall survival benefit in NATALEE in the adjuvant setting (Slamon et al., NEJM 2024, see Sources). A fourth-to-market CDK4/6 inhibitor with a tolerability claim and no comparative phase 3 data against the three approved agents has limited commercial pull, even if the mechanism is intact.

How to prevent this next time

Two quantitative tools would have changed the calculus before EQRx committed the spend.

First, an explicit Bayesian posterior on commercial-go probability rather than technical-go probability. The technical-go posterior for lerociclib was high. The commercial-go posterior, given three approved competitors with overall survival data emerging, was structurally lower:

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

Plugging in a prior anchored on fourth-to-market HR+/HER2- breast cancer launches (median peak sales below 200 million USD against incumbents with embedded oncology sales forces), the commercial PP(success) falls below 0.15 even with a 90 percent technical PP(success). That gap was identifiable in 2021.

Second, a competitive landscape red-team using a structured base-rate adjustment. Open Targets v26.03 currently lists 12 distinct programs in clinical development against CDK6 and 18 against CDK4, with 4 in approval or Phase 3 (drugAndClinicalCandidates). Historical base rates for fourth-or-later entrants in a saturated oncology class show median time-to-acquisition or shutdown of 38 months from Phase 2 entry (DiMasi & Grabowski, J Health Econ 2016, see Sources). NCT05085002 was at month 21 when EQRx merged. The base rate flagged the risk before the corporate event triggered it.

The single highest leverage change would have been triggering a sponsor-handoff clause in the lerociclib development agreement with Genor Biopharma at the point of the EQRx-Revolution merger announcement, preserving Western development under a non-orphaned sponsor.

What this means for similar programs

Two other oral CDK4/6 inhibitors are still in Phase 1 or Phase 2 development against HR+ metastatic breast cancer (PF-07220060, saruparib-class combinations, intermittent dosing schedules). Their sponsors should be modeling commercial-go probability as the binding constraint rather than technical-go probability. Programs differentiating on tolerability alone, without a hard comparative-effectiveness endpoint against a current standard, are highly exposed to corporate-event risk because they cannot justify the cost of head-to-head trials. Sponsors entering crowded class spaces should secure either a synthetic-lethality combination strategy (CDK4-selective in PIK3CA-mutant disease, CDK4/6 plus oral SERD in ESR1-mutant disease) or a structured exit option before initiating Phase 3.

Open questions

• Will the lerociclib safety dataset from NCT05085002 be published? Average 237.4 days on treatment across 100 patients is publishable safety and pharmacokinetic material that should not be lost to a corporate shutdown.
• Does the LEONARDA-1 Chinese readout support an ex-China filing by Genor or a successor licensee, or is the dataset trapped by sponsor structure?
• What is the marginal value of a CDK4-selective inhibitor (PF-07220060, atirmociclib) in PIK3CA-mutant HR+ breast cancer relative to a pan-CDK4/6 incumbent?

Sources

1. • ClinicalTrials.gov: NCT05085002 (Phase 2 lerociclib advanced breast cancer), terminated 2026-05-15. https://clinicaltrials.gov/study/NCT05085002 - Bisi JE, Sorrentino JA, Jordan JL, et al. Preclinical development of G1T38, a novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic. Oncotarget 2017, volume 8, pages 42343 to 42358.https://- Xu B, Zhang Q, Luo Y, et al. Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on endocrine therapy (LEONARDA-1). Nat Commun 2025, volume 16, article 611.https://- Andreano KJ, Wardell SE, Baker JG, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat 2020, volume 180, pages 635 to 646.https://- Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer (NATALEE). N Engl J Med 2024, volume 390, pages 1080 to 1091. https://- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019, volume 20, pages 273 to 286. https://- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry, new estimates of R&D costs. J Health Econ 2016, volume 47, pages 20 to 33. https://- Open Targets Platform v26.03. https://platform.opentargets.org/target/ENSG00000105810 (CDK6). - EQRx and Revolution Medicines merger, SEC 8-K filing, 2023-08-01. - ChEMBL CHEMBL3904602 (lerociclib). https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3904602.